[ad_1]
Original title: AstraZeneca discontinued in 12 European countries, France: No cases of abnormal reaction, will continue to be used Source: Observer.com
(Observer Network News) Due to the frequent occurrence of blood clots and even deaths among vaccinators, 12 countries in Europe have discontinued the use of the AstraZeneca vaccine.
When many countries question the safety of the AstraZeneca vaccine, the French National Medicines Agency declared on the 13th that the country has not had serious side effects such as deaths and thrombosis, so it decided to continue with the vaccination plan with the AstraZeneca vaccine.
On March 14, the British company AstraZeneca issued a statement to defend itself, insisting that its review of vaccine safety data showed that no batch of vaccines had quality problems, and there was no evidence that it increased the risk of stroke. .
France: no cases of thrombosis have been reported and will continue to be used
On March 13 local time, the French National Medicines Agency (ANSM) released the country’s latest report on the side effects of the new vaccination crown.
The report data shows that, as of March 4, AstraZeneca has delivered 454,500 doses of the new crown vaccine to France, and a total of 3013 people have experienced adverse side effects after the injection, the ratio is only 0, 66%. This number is less than 1%, but greater than 0.12% for the Modena vaccine and 0.19% for the Pfizer vaccine.
The French National Medicines Agency published data on the 13th
Two-thirds of these side effects are considered “non-serious,” including pain at the injection site and a mild fever; about 10% of side effects are nausea or vomiting, headache, and dizziness.
It is worth mentioning that in the vaccine delivered by AstraZeneca to France, there were 316,800 doses of ABV5300, half of which have been used, and there were no deaths or cases of “abnormal reactions”, including thrombosis.
Previously, following the death of two vaccinators and the appearance of symptoms of pulmonary embolism, Austria announced the suspension of the vaccination of batches of AstraZeneca ABV5300. However, the French National Medicines Agency stated in the report: “At this stage, there is no indication that there are specific problems with the ABV5300 lot, or that the vaccine has caused adverse reactions in Austria.”
The report also added:The European Medicines Agency (EMA) recommends that AstraZeneca vaccines continue to be used in Europe, and the French National Medicines Agency supports this, “but if the data change, this position may change.”
The European Medicines Regulatory Agency (EMA) is investigating whether the AstraZeneca vaccine is linked to a large number of thrombosis case reports. So far, there is no evidence to show that there is a direct connection between the two. The EMA said on the 11th that they believe the benefits of vaccination continue to outweigh the risks and that the vaccine can continue to be used while investigations into deaths from blood clots are still ongoing.
The Irish vaccinated with AstraZeneca, in the pop-up image12 European countries suspend suspension, AstraZeneca speaks urgently
Although France still chooses to believe in AstraZeneca, the controversy over the vaccine’s side effects is spreading across the European continent.
Austria was the first to warn of the potential dangers of the AstraZeneca vaccine. As a preventive measure, Italy, Austria, Estonia, Latvia, Lithuania, Luxembourg and Romania have stopped using certain batches of vaccines.
On March 11, Denmark announced that a woman had died after being vaccinated with AstraZeneca and had a blood clot in her body. To investigate whether there is a link between the vaccine and blood clots, Denmark became the first country to completely discontinue vaccination of AstraZeneca. Since then, Norway and Iceland have also joined.
On March 14, Ireland and the Netherlands announced the suspension of use of the new British corona vaccine AstraZeneca. So far, 12 countries in Europe have discontinued the use of the AstraZeneca vaccine.
On the same day, AstraZeneca issued a statement to defend itself, saying its review of vaccinator safety data showed no vaccine batch was confirmed to have quality problems, and there was no evidence that the risk of blood clots increased. after vaccination. .
AstraZeneca statement
AstraZeneca stated that after careful review of all available safety data for more than 17 million vaccinators in the UK and EU, in any age group, sex, vaccination lot or any specific country and region, “no Vaccination has been found to cause lung disease. Evidence of an increased risk of embolism, deep vein thrombosis or thrombocytopenia “.
Ann Taylor, AstraZeneca’s Chief Medical Officer, said: “Currently, approximately 17 million people in the European Union and the UK have been vaccinated with our vaccine. The number of cases of thrombosis reported by this group is less than the hundreds of cases. expected by the general population He added that public attention to individual cases has increased during the epidemic, so the company is monitoring drug safety with high standards to ensure public safety.
Massive information, accurate interpretation, all in the Sina Finance APP
